Physician profile
Rupal Oquinn
NPI 1033319991
$23,728.92
in general payments reported to CMS, 2019-2025
9 companies · $2,281 in 2025
The $2,281 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,789 · 2022: $8,903 · 2023: $6,102 · 2024: $1,655 · 2025: $2,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,102 · Honoraria: $4,000 · Food and Beverage: $936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,101.50 |
| Honoraria | $4,000.00 |
| Food and Beverage | $935.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $10,854.49 | 2021-2025 | Calquence |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $6,276.71 | 2022-2025 | Lifevest |
| Astrazeneca Uk Limited | $6,159.00 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $289.46 | 2021-2025 | Optimizer, Optimizer |
| Janssen Pharmaceuticals, INC | $45.34 | 2024 | Xarelto |
| Atricure, INC. | $38.41 | 2023 | |
| Cvrx, INC. | $24.40 | 2024 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.92 | 2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $19.19 | 2024 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupal Oquinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.